Mirabegron Versus Solifenacin in Multiple Sclerosis Patients With Overactive Bladder Symptoms: A Prospective Comparative Nonrandomized Study


      To determine the patient-perceived effectiveness and tolerability of mirabegron compared to solifenacin in a multiple sclerosis (MS) population with overactive bladder (OAB) symptoms.


      MS patients with OAB symptoms who were not on medication for their urinary symptoms at enrollment were prospectively recruited. Patients enrolled in years 1-2 were prescribed mirabegron, whereas patients enrolled in years 3-4 were prescribed solifenacin. At enrollment and 6-week follow-up, patients completed several patient reported outcome measures. The primary outcome was change in OAB Questionnaire Short Form (OAB-q SF) symptom severity and minimal clinically important difference (MCID) achievement. The Patient Assessment of Constipation Symptoms (PAC-SYM) was used to assess bowel function over the treatment period.


      Sixty-one patients were enrolled. The majority of the mirabegron (70%) and the solifenacin (69%) group achieved the OAB-q SF symptom severity MCID. The solifenacin group had a statistically significant greater decrease in its end of study OAB-q SF score (Δ = −37.87 vs −20.43, P = .02). Constipation improved in the mirabegron group and worsened in the solifenacin group (ΔPAC-SYM = −0.38 vs +0.22; P = .02), with 30% of patients prescribed solifenacin experiencing worsening above the MCID threshold.


      Among MS patients, we demonstrated similar response rates to mirabegron and solifenacin, with approximately 50%-70% achieving each patient reported outcome measure's MCID. Though this small study showed some short-term evidence that improvement in urinary symptom severity was greater with solifenacin, this potential benefit must be weighed against the observed risk of worsening constipation. Further studies are needed to confirm these findings.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Compston A
        • Coles A
        Multiple sclerosis.
        Lancet. 2008; 372: 1502-1517
        • Khalaf KM
        • Coyne KS
        • Globe DR
        • Armstrong EP
        • Malone DC
        • Burks J
        Lower urinary tract symptom prevalence and management among patients with multiple sclerosis.
        Int J MS Care. 2015; 17: 14-25
        • McCombe PA
        • Gordon TP
        • Jackson MW
        Bladder dysfunction in multiple sclerosis.
        Expert Rev Neurother. 2009; 9: 331-340
        • Sadiq A
        • Brucker BM.
        Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients.
        Curr Urol Rep. 2015; 16: 44
        • Amarenco G
        • Sutory M
        • Zachoval R
        • et al.
        Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study.
        Neurourolo Urodyn. 2017; 36: 414-421
        • Paily A
        • Preziosi G
        • Trivedi P
        • Emmanuel A
        Anti-muscarinic drugs increase rectal compliance and exacerbate constipation in chronic spinal cord injury: Anti-muscarinic drug effect on neurogenic bowel.
        Spinal Cord. 2019; 57: 662-668
        • Grzegorski T
        • Losy J.
        Cognitive impairment in multiple sclerosis - a review of current knowledge and recent research.
        Rev Neurosci. 2017; 28: 845-860
        • Nitti VW
        • Auerbach S
        • Martin N
        • Calhoun A
        • Lee M
        • Herschorn S
        Results of a randomized phase III trial of mirabegron in patients with overactive bladder.
        J Urol. 2013; 189: 1388-1395
        • Lozano-Ortega G
        • Walker D
        • Rogula B
        • et al.
        The relative efficacy and safety of mirabegron and onabotulinumtoxinA in patients with overactive bladder who have previously been managed with an antimuscarinic: a network meta-analysis.
        Urology. 2019; 127: 1-8
        • Herschorn S
        • Staskin D
        • Tu LM
        • et al.
        Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
        Health Qual Life Outcomes. 2018; 16: 69
        • Khullar V
        • Amarenco G
        • Angulo JC
        • et al.
        Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
        Eur Urol. 2013; 63: 283-295
        • Welk B
        • Hickling D
        • McKibbon M
        • Radomski S
        • Ethans K
        A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction.
        Neurourol Urodyn. 2018; 37: 2810-2817
        • Krhut J
        • Borovicka V
        • Bilkova K
        • et al.
        Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-prospective, randomized, double-blind, placebo-controlled study.
        Neurourol Urodyn. 2018; 37: 2226-2233
        • Carlson KV
        • Rovner ES
        • Nair KV
        • Deal AS
        • Kristy RM
        • Schermer CR
        Factors associated with improvements in patient-reported outcomes during mirabegron or antimuscarinic treatment of overactive bladder syndrome: a registry study (PERSPECTIVE).
        Adv Ther. 2019; 36: 1906-1921
        • Chapple CR
        • Nitti VW
        • Khullar V
        • et al.
        Onset of action of the beta3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder.
        World J Urol. 2014; 32: 1565-1572
        • Coyne KS
        • Thompson CL
        • Lai JS
        • Sexton CC
        An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF".
        Neurourol Urodyn. 2015; 34: 255-263
        • Yalcin I
        • Bump RC.
        Validation of two global impression questionnaires for incontinence.
        Am J Obstet Gynecol. 2003; 189: 98-101
        • Viktrup L
        • Hayes RP
        • Wang P
        • Shen W
        Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
        BMC Urol. 2012; 12: 30
        • Neri L
        • Conway PM
        • Basilisco G
        Confirmatory factor analysis of the Patient Assessment of Constipation-Symptoms (PAC-SYM) among patients with chronic constipation.
        Qual Life Res. 2015; 24: 1597-1605
        • Blanker MH
        • Alma HJ
        • Devji TS
        • Roelofs M
        • Steffens MG
        • van der Worp H
        Determining the minimal important differences in the International Prostate Symptom Score and Overactive Bladder Questionnaire: results from an observational cohort study in Dutch primary care.
        BMJ Open. 2019; 9e032795
        • Yiannakou Y
        • Tack J
        • Piessevaux H
        • et al.
        The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference.
        Aliment Pharmacol Ther. 2017; 46: 1103-1111
        • Zachariou A
        • Filiponi M
        • Baltogiannis D
        • et al.
        Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron.
        Can J Urol. 2017; 24: 9107-9113
        • Robinson D
        • Kelleher C
        • Staskin D
        • et al.
        Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
        Neurourol Urodyn. 2018; 37: 394-406
        • Cardozo L
        • Amarenco G
        • Pushkar D
        • et al.
        Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
        BJU Int. 2013; 111: 804-810
        • El Helou E
        • Labaki C
        • Chebel R
        • et al.
        The use of mirabegron in neurogenic bladder: a systematic review.
        World J Urol. 2019; ([published online ahead of print, 2019 Dec 5])